RALLYBIO CORPORATION

RLYB ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item FY2025 FY2024
Revenue $858.0K $636.0K
Cost of Revenue
Gross Profit
Gross Margin
Operating Expenses
Research & Development $19.6M $41.5M
SG&A Expense $14.3M $19.6M
Operating Income $-33.1M $-60.5M
Operating Margin -3,853.6% -9,511.9%
Interest Expense
Pretax Income $-9.0M $-55.5M
Income Tax Expense $0 $0
Net Income $-9.0M $-57.8M
Net Margin -1,046.4% -9,084.1%
EPS (Basic) $-1.59 $-10.61
EPS (Diluted) $-1.59 $-10.61
Shares Outstanding (Basic) 5.6M 5.4M
Shares Outstanding (Diluted) 5.6M 5.4M
Dividends Per Share